Home > About us > About Basetra
About Basetra

Basetra  is a biotech service company with cutting edge technology and ISO15198 central laboratory,located in Shanghai & Hong Kong. We focus on developing the next generation technology for rare cell capture in vivo, single cell-based diagnosis and whole-genome sequencing.

Equipped with the most advanced instruments and world-leading technologies, Our professional team consists of world renowned scientists and business executives, with researchers from the University of California at Berkeley (UC Berkeley), Lawrence Berkeley National Laboratory (LBNL), Children’s Hospital of Oakland Research Institute (CHORI), University of California at San Francisco (UCSF),the University of Tokyo.  Basetra has also established on-going collaboration with top-tier medical institutions globally.  We have developed three key platforms for (1) cell capture, (2) single cell diagnosis and (3) whole-genome sequencing. All these achievement have made Basetra one of the leading medical diagnostics companies in the fields of cell-based molecular diagnosis.

Basetra has already developed world-leading technology for cell capture, which is a unique combination of microfluidic cytometry platform and next generation sequencing(NGS) technologies. The sequencing and analysis teams of Basetra, originally from the Lawrence Berkeley National Laboratory, the Joint Genome Institute, and BGI, have more than 20 years’ experience in sequencing technology development.

Our myCyte™ Peripheral Blood Cells Capture System and myGCTA™ Personalized Digital Health Management Platform make Basetra one of the few companies in the world that have achieved clinical diagnosis at single cell level.  The myCyte™ platform adopts an advanced cell capture technology, reaching at one out of one billion accuracy, to eliminate false positive and false negative misdiagnosis to maintain the activities and properties of live single cell for further testing and characterization. The myGCTA™ platform is a data analysis framework for whole-genome sequencing technology from limited number of cells. It can automatically process the sequencing data and identify disease risk associated with genetic abnormalities.

Basetra holds several U.S. and international patents. Our service covers major provinces and cities in mainland China. Our BabyGuard™ Cytometry-based Non-invasive Prenatal Testing (cytoNIPT) diagnosis technology was awarded  the first prize in the ‘2013 China Science Technology Business Grand Competition’.

Currently, Basetra has launched non-invasive prenatal diagnosis services, providing the most professional services with cutting-edge biological technologies and dedicating ourselves to the development of next generation biotechnology for improving human health.